Mercodia Total GLP-1 NL-ELISA provides a chemiluminescent method for the quantitative determination of amidated GLP-1 (glucagon-like-peptide-1) in human serum or plasma samples.
The assay has a low sample volume of 25 μL, a broad measuring range (0.9 - 940 pmol/L) and a low functional sensitivity (LLOQ 1 pmol/L), allowing for precise detection in both fasting samples as well as sampels with highly elevated levels.
Measuring the predominating isoform GLP-1 (9-36) amide gives a good picture of the downstream secretion and action of GLP-1.
Watch this short clip with Professor Jens Juul Holst to learn more.
The assay is the first in the new chemiluminescent product line “Northern Lights”.
Read the Directions for Use
A high quality enzyme immunoassay with chemiluminescent detection for the quantitative determination of amidated Glucagon-like peptide-1 (GLP-1) in human samples.
The assay has been validated according to CLSI, FDA and EMA guidelines.
Analytical sensitivity (or Capability of Detection) is 0.65 pmol/L as determined by the methodology described in ISO11843-Part 4. Functional sensitivity (or Lower Limit of Quantification, LLOQ) is 1.0 pmol/L as determined according to FDA/EMA guidelines.
Dilutional Linearity and Parallelism
Mean recovery for dilutional linearity is 99% (93-106%) with precision of the final concentration across all dilutions ≤ 3%. Mean recovery for parallelism is 92% (82-109%) with precision between samples in the dilution series ≤ 11%.
Fasting levels of total GLP-1 in plasma samples from 128 healthy indivivuals were determined according to CLSI guidelines with the Mercodia assay. The 90% confidence interval was calculated to 0.9 - 18 pmol/L with a mean of 5.8 pmol/L.
The Mercodia Total GLP-1 NL-ELISA can be used with both serum and EDTA plasma samples. In addition, P800 tubes from BD™ (Becton Dickinson) have been validated for use in the assay.
Mercodia Total GLP-1 NL-ELISA is a solid phase two-site enzyme immunoassay based on the sandwich technique, in which two monoclonal antibodies are directed against separate antigenic determinants on the Glucagon-like peptide-1 (GLP-1) molecule. GLP-1 in the sample reacts with anti-GLP-1 antibodies bound to microtitration wells and peroxidase-conjugated anti-GLP-1 antibodies in the solution.
The following cross-reactions have been tested:
|GLP-1 (1-36) amide||88%|
|GLP-1 (7-36) amide||93%|
|GLP-1 (9-36) amide||100%|
*Dulaglutide will interfere in the assay.
n.d. = not detectable
Total GLP-1 NL-ELISA